MARKET

ALEC

ALEC

Alector
NASDAQ
1.700
+0.030
+1.80%
After Hours: 1.700 0 0.00% 17:51 02/14 EST
OPEN
1.670
PREV CLOSE
1.670
HIGH
1.756
LOW
1.665
VOLUME
306.04K
TURNOVER
--
52 WEEK HIGH
7.58
52 WEEK LOW
1.550
MARKET CAP
166.49M
P/E (TTM)
-0.9950
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALEC last week (0210-0214)?
Weekly Report · 15h ago
Weekly Report: what happened at ALEC last week (0203-0207)?
Weekly Report · 02/10 09:16
Weekly Report: what happened at ALEC last week (0127-0131)?
Weekly Report · 02/03 09:16
Weekly Report: what happened at ALEC last week (0120-0124)?
Weekly Report · 01/27 09:17
Vigil: Now A 'Hold' Based On Two New Pipeline Developments
Seeking Alpha · 01/23 23:08
Discovering 3 US Penny Stocks With Market Caps Below $200M
Simply Wall St · 01/21 17:14
Alector’s Strategic Advancements and Promising Pipeline: A Buy Rating by Thomas Shrader
TipRanks · 01/21 12:56
Weekly Report: what happened at ALEC last week (0113-0117)?
Weekly Report · 01/20 09:16
More
About ALEC
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Webull offers Alector Inc stock information, including NASDAQ: ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.